

SEATTLE GENETICS INC /WA  
Form 8-K  
September 28, 2004

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**Current Report Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 27, 2004**

---

**Seattle Genetics, Inc.**

(Exact name of Registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**0-32405**  
(Commission File Number)

**91-1874389**  
(I.R.S. Employer

Identification No.)

**21823 30<sup>th</sup> Drive SE**  
**Bothell, Washington 98021**

(Address of principal executive offices, including zip code)

Edgar Filing: SEATTLE GENETICS INC /WA - Form 8-K

(425) 527-4000

(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into Material Definitive Agreement.**

On September 28, 2004, Seattle Genetics, Inc. issued a press release announcing it entered into a Collaboration Agreement with Bayer Pharmaceuticals Corporation ( Bayer ) dated September 27, 2004 that provides Bayer with rights to utilize Seattle Genetics ADC technology to link cell-killing drugs to antibodies against a specific tumor target selected by Bayer. This transaction is described in greater detail in a copy of the press release furnished herewith as Exhibit 99.1 below and such disclosure is incorporated by reference from Exhibit 99.1 below into this Item 1.01.

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits.

99.1 Press Release of Seattle Genetics, Inc. dated September 28, 2004.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SEATTLE GENETICS, INC.**

Date: September 28, 2004

By: /s/ Clay B. Siegall

\_\_\_\_\_  
Clay B. Siegall

President and Chief Executive Officer

**INDEX TO EXHIBITS**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press Release of Seattle Genetics, Inc. dated September 28, 2004.